• 7-Ethyl-10-hydroxycamptothecin: Assay Interpretation

  2026-09-20

  7-Ethyl-10-hydroxycamptothecin, also known as SN-38, is best interpreted through linked molecular, cell-cycle, and apoptosis readouts. This guide develops an evidence-weighted assay framework that distinguishes topoisomerase I trapping from downstream phenotype in advanced colon cancer research.

• EZ Cap™ Human PTEN mRNA (ψUTP): Lab Guide

  2026-09-19

  A scenario-based guide to using EZ Cap™ Human PTEN mRNA (ψUTP), SKU R1026, in cell viability, proliferation, and cytotoxicity workflows. It explains experimental controls, RNA handling, pathway-level interpretation, and practical criteria for selecting a modified human PTEN mRNA reagent.

• Morin: From Flavonoid to Mechanistic Probe

  2026-09-19

  Morin is a multifunctional flavonoid whose value extends beyond antioxidant screening. This article explains how AMPD-focused mitochondrial assays, podocyte injury models, and aluminum-ion fluorescence can be integrated without overstating preclinical evidence.

• ATS-9R: Targeted Gene Silencing in Adipose Tissue

  2026-09-18

  ATS-9R enables Prohibitin-directed delivery of siRNA, shRNA, and sgRNA/Cas9 cargoes to white adipose tissue and adipose tissue macrophages. Its practical value lies in combining non-viral nucleic acid condensation with a workflow suited to obesity-associated inflammation research, insulin resistance amelioration, and GDM models.

• BMS-345541 Hydrochloride: IKK Inhibitor Workflows

  2026-09-17

  Use BMS-345541 hydrochloride to separate NF-κB pathway control from RIPK1-driven cell death in inflammation and leukemia models. This workflow combines selective IKK inhibition, time-resolved signaling assays, and practical formulation controls for more interpretable results.

• Acetylcholine Chloride in Gut–Brain Assays

  2026-09-17

  Acetylcholine Chloride can serve as a defined acetylcholine neurotransmitter perturbation for dissecting gut–vagus–brain cholinergic signaling. This article connects the Bacteroides fragilis epilepsy study to assay design, causal controls, and interpretation of receptor-level data.

• EZ Cap EGFP mRNA 5-moUTP Workflow Guide

  2026-09-17

  Build reproducible reporter, delivery, and translation studies with a Cap1-structured, 5-moUTP-modified EGFP transcript. This guide connects practical bench workflows with machine-learning-assisted lipid nanoparticle screening and cell-state-aware assay design.

• p-Cresyl Sulfate: From Exposure to Valve Risk

  2026-09-16

  p-Cresyl sulfate is a protein-bound uremic solute linking chronic kidney disease to endothelial and valvular injury. This article translates klotho/SIRT1 findings into a practical framework for selecting models, controlling exposure, and interpreting cardiovascular assays.

• β-Elemene: AMPK-Centered Assay Strategy

  2026-09-15

  β-Elemene research is strengthened by connecting adipocyte phenotype, glucose handling, and AMPK signaling in one decision-oriented assay framework. This guide interprets the latest 3T3-L1 evidence while defining practical boundaries for apoptosis, neuroprotection, inflammation, and analytical studies.

• Balsalazide Disodium: An Assay-First Guide

  2026-09-15

  Balsalazide disodium is more than a colon-targeted 5-ASA prodrug: it is a useful model for connecting chemical activation, tissue localization, and inflammatory readouts. This assay-first guide explains how to use the compound, interpret radiotracer evidence, and avoid common translational errors.

• Ibrexafungerp Against Fluconazole-Resistant Candida auris

  2026-09-14

  The reference study shows that ibrexafungerp, also known as MK 3118, retains consistent in vitro activity against 54 Candida auris isolates and improves outcomes in a neutropenic mouse model even when therapy begins after infection is established. Its delayed-treatment design is particularly relevant to invasive candidiasis, where diagnosis and treatment often do not occur immediately.

• CCCP for Mitochondrial Morphology Workflows

  2026-09-14

  CCCP provides a controlled chemical perturbation for testing mitochondrial membrane-potential dependence in live-cell imaging and AI-assisted morphology assays. This workflow connects carbonyl cyanide m-chlorophenyl hydrazine with urine-derived stem cell research while clearly separating experimental mitochondrial stress modeling from Alzheimer’s disease biomarker validation.

• CS18 TopBP1 Inhibition Enhances PARP Blockade

  2026-09-13

  The reference study develops CS18, a structurally distinct inhibitor of the TopBP1 BRCT7/8 interface, using docking-guided screening and structure–activity relationship optimization. CS18 disrupts oncogenic TopBP1 complexes, enhances PARP inhibitor activity, and restores osimertinib sensitivity in resistant EGFR-mutated NSCLC models, supporting a strategy for targeting resistance-associated pathway dependencies.

• Separating Growth Inhibition from Cancer Cell Death

  2026-09-12

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for distinguishing proliferative arrest from actual cell killing, improving interpretation of in vitro drug-response experiments and the design of translational assays.

• DMH1: ALK2 Inhibitor for Organoid Assays

  2026-09-12

  DMH1 provides a selective way to test how BMP signaling influences organoid self-renewal, differentiation, and disease phenotypes. Its defined ALK2 activity also supports translational workflows in non-small cell lung cancer research, including migration, signaling, and viability assays.

8666 records 1/578 page Next 12345 下5页 Last page